AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30514326 — intervention group
Group type: EXPERIMENTAL
Intervention: Lognormal distribution analysis
Number of subjects: 0
Study 30514326 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-parameter lognormal distribution
Number of subjects: 0
Study 30514326 — intervention group
Group type: EXPERIMENTAL
Intervention: Lognormal distribution approach
Number of subjects: 0
Study 30514390 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab plus olaparib
Number of subjects: 17
Study 30515367 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus plus exemestane
Number of subjects: 241
Study 30515430 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic HIV
Number of subjects: 149
Study 30515430 — intervention group
Group type: COMPARATOR
Intervention: Elite Controllers
Number of subjects: 149
Study 30515430 — intervention group
Group type: COMPARATOR
Intervention: HIV-negative controls
Number of subjects: 149
Study 30515599 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian IRT Model
Number of subjects: 940
Study 30515765 — intervention group
Group type: COMPARATOR
Intervention: Cannabidiol
Number of subjects: 23
Study 30516520 — intervention group
Group type: EXPERIMENTAL
Intervention: AmpliPrep
Number of subjects: 0
Study 30516520 — intervention group
Group type: EXPERIMENTAL
Intervention: MagNA Pure
Number of subjects: 0
Study 30516520 — intervention group
Group type: EXPERIMENTAL
Intervention: QIAcube QBK
Number of subjects: 0
Study 30516520 — intervention group
Group type: EXPERIMENTAL
Intervention: QIAcube VRK
Number of subjects: 0
Study 30516520 — intervention group
Group type: COMPARATOR
Intervention: Manual method (Instant Virus RNA/DNA kit)
Number of subjects: 0
Study 30517603 — intervention group
Group type: EXPERIMENTAL
Intervention: Palivizumab
Number of subjects: 21107
Study 30517722 — intervention group
Group type: EXPERIMENTAL
Intervention: Overnight spot samples with the Tanaka equation
Number of subjects: 86
Study 30517722 — intervention group
Group type: EXPERIMENTAL
Intervention: Overnight spot samples with the Brown equation
Number of subjects: 86
Study 30517722 — intervention group
Group type: COMPARATOR
Intervention: Other equations (not specified)
Number of subjects: 86
Study 30517727 — intervention group
Group type: EXPERIMENTAL
Intervention: Hazelnuts (∼57 g/d) for 16 weeks
Number of subjects: 32
Study 30517728 — intervention group
Group type: EXPERIMENTAL
Intervention: Normozygous sickle cell children (HbAA)
Number of subjects: 435
Study 30517728 — intervention group
Group type: EXPERIMENTAL
Intervention: Sickle cell trait (HbAS)
Number of subjects: 435
Study 30517728 — intervention group
Group type: EXPERIMENTAL
Intervention: Normozygous (αα/αα) for α+-thalassemia
Number of subjects: 435
Study 30517728 — intervention group
Group type: EXPERIMENTAL
Intervention: Heterozygous (-α/αα) for α+-thalassemia
Number of subjects: 435
Study 30517728 — intervention group
Group type: EXPERIMENTAL
Intervention: Homozygous (-α/-α) for α+-thalassemia
Number of subjects: 435
Study 30518443 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolysis treatment group (110 patients)
Number of subjects: 204
Study 30518443 — intervention group
Group type: COMPARATOR
Intervention: Non-thrombolysis treatment group (94 patients)
Number of subjects: 204
Study 30518449 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported late sleep midpoint
Number of subjects: 10038
Study 30518449 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported short sleep duration
Number of subjects: 10038
Study 30518449 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported sleep midpoint
Number of subjects: 10038
Study 30518449 — intervention group
Group type: EXPERIMENTAL
Intervention: Concordance between sleep diary and actigraphy for short sleep duration
Number of subjects: 10038
Study 30518449 — intervention group
Group type: EXPERIMENTAL
Intervention: Concordance between sleep diary and actigraphy for sleep midpoint
Number of subjects: 10038
Study 30518502 — intervention group
Group type: EXPERIMENTAL
Intervention: Axicabtagene ciloleucel (target dose of 2 × 10^5 cells) administered on day 0
Number of subjects: 108
Study 30518502 — intervention group
Group type: EXPERIMENTAL
Intervention: Axicabtagene ciloleucel
Number of subjects: 108
Study 30518517 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured communication intervention for family centered rounds; includes structured, high reliability communication, written real-time summaries, formal training for healthcare providers, and strategies for teamwork.
Number of subjects: 3106
Study 30518543 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated Aries molecular testing method
Number of subjects: 0
Study 30519456 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 30519467 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Focused Ultrasound (HIFU) under MR guidance
Number of subjects: 17
Study 30519481 — intervention group
Group type: EXPERIMENTAL
Intervention: GO-OUT program (1-day workshop and 9-week outdoor walking group)
Number of subjects: 9
Study 30519481 — intervention group
Group type: COMPARATOR
Intervention: Workshop alone
Number of subjects: 9
Study 30519877 — intervention group
Group type: EXPERIMENTAL
Intervention: Life support-based comprehensive treatment regimen including mechanical life support, immunological modulation with glucocorticoids and immunoglobulin, and antiviral reagents (neuraminidase inhibitor)
Number of subjects: 0
Study 30520001 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion XL 150 mg once daily for 5 days, then 300 mg once daily from days 6 to 14
Number of subjects: 16
Study 30520001 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion XL
Number of subjects: 16
Study 30520349 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD shocks during sports participation
Number of subjects: 129
Study 30520349 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventricular tachycardia/ventricular fibrillation storm
Number of subjects: 129
Study 30520349 — intervention group
Group type: EXPERIMENTAL
Intervention: Lead malfunction rates
Number of subjects: 129
Study 30520689 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional macrophage migration inhibitory factor (MIF) promoter polymorphism
Number of subjects: 0
Study 30521125 — intervention group
Group type: EXPERIMENTAL
Intervention: Haematuria cancer risk score (HCRS)
Number of subjects: 4195
Study 30521125 — intervention group
Group type: COMPARATOR
Intervention: UK National Institute for Health and Clinical Excellence guidelines
Number of subjects: 4195
Study 30521125 — intervention group
Group type: COMPARATOR
Intervention: American Urological Association guidelines
Number of subjects: 4195
Study 30521533 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin treatment
Number of subjects: 3962
Study 30521759 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 30522091 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-reported behavior problems on the Child Behavior Checklist (CBCL)
Number of subjects: 0
Study 30522091 — intervention group
Group type: EXPERIMENTAL
Intervention: Internalizing, affective, and pervasive development problem behavior scores on the CBCL
Number of subjects: 0
Study 30522091 — intervention group
Group type: EXPERIMENTAL
Intervention: Externalizing and anxiety problems on the CBCL
Number of subjects: 0
Study 30522091 — intervention group
Group type: EXPERIMENTAL
Intervention: CBCL scores for boys and girls
Number of subjects: 0
Study 30522571 — intervention group
Group type: EXPERIMENTAL
Intervention: Transtheoretical Model intervention
Number of subjects: 0
Study 30522646 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI) with drug-eluting stents
Number of subjects: 1900
Study 30522646 — intervention group
Group type: COMPARATOR
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 1900
Study 30522700 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (10 mg/kg every 2 weeks for ≤24 months)
Number of subjects: 26
Study 30522968 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 30522992 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual psychopharmacological therapy plus the Social-Local-Mobile app
Number of subjects: 240
Study 30522992 — intervention group
Group type: COMPARATOR
Intervention: Usual psychopharmacological therapy
Number of subjects: 240
Study 30523027 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemia identified by metrics of retinal vessel density
Number of subjects: 142
Study 30523027 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurodegeneration identified by thinning of the retinal nerve fiber layer and/or ganglion cell layer
Number of subjects: 142
Study 30523027 — intervention group
Group type: EXPERIMENTAL
Intervention: Edema identified by thickening of the inner nuclear layer, outer plexiform layer, or full retina
Number of subjects: 142
Study 30523039 — intervention group
Group type: EXPERIMENTAL
Intervention: Various modifiable risk factors (e.g., diet, supplement use, physical activity)
Number of subjects: 0
Study 30523039 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomarkers (e.g., metabolomic, transcriptomic, metagenomic, genetic, epigenetic, proteomic markers)
Number of subjects: 0
Study 30523489 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitated recall to clinicians
Number of subjects: 327
Study 30523489 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood drug concentrations in plasma
Number of subjects: 327
Study 30523489 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-report in online surveys
Number of subjects: 327
Study 30523735 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolysis extended to 9 hours from stroke onset
Number of subjects: 0
Study 30523735 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30523748 — intervention group
Group type: EXPERIMENTAL
Intervention: UCB expanded ex vivo with nicotinamide
Number of subjects: 36
Study 30523748 — intervention group
Group type: COMPARATOR
Intervention: Standard UCB transplantation (comparator)
Number of subjects: 36
Study 30523943 — intervention group
Group type: EXPERIMENTAL
Intervention: Couch motion (dynamic tracking)
Number of subjects: 100
Study 30523943 — intervention group
Group type: COMPARATOR
Intervention: Couch static (control)
Number of subjects: 100
Study 30524317 — intervention group
Group type: EXPERIMENTAL
Intervention: Baclofen
Number of subjects: 0
Study 30524317 — intervention group
Group type: COMPARATOR
Intervention: Antidepressants
Number of subjects: 0
Study 30524509 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (varenicline + nicotine patch + nicotine lozenge)
Number of subjects: 36
Study 30524702 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-TNF-alpha biologic infliximab
Number of subjects: 0
Study 30524719 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative isometric exercise (PIE) for 8 weeks
Number of subjects: 40
Study 30524719 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 40
Study 30524746 — intervention group
Group type: COMPARATOR
Intervention: Recommended gestational weight gain
Number of subjects: 80
Study 30525116 — intervention group
Group type: EXPERIMENTAL
Intervention: LEV 1,000-3,000 mg/day
Number of subjects: 251
Study 30525116 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 251
Study 30525443 — intervention group
Group type: EXPERIMENTAL
Intervention: Custom-designed irinotecan silicasome (Ir-silicasome)
Number of subjects: 0
Study 30525443 — intervention group
Group type: COMPARATOR
Intervention: Onivyde
Number of subjects: 0
Study 30525443 — intervention group
Group type: COMPARATOR
Intervention: Free drug (irinotecan)
Number of subjects: 0
Study 30525951 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium infantis M-63 (1×10^9 CFU)
Number of subjects: 20
Study 30525951 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 20
Study 30526163 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramedullary nails with cannulated screws
Number of subjects: 96
Study 30526163 — intervention group
Group type: COMPARATOR
Intervention: Inverted triangular cannulated compression screws
Number of subjects: 96
Study 30526163 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 96
Study 30526213 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytisine, a partial agonist for the α4β2 nicotinic acetylcholine receptor, administered in ascending single doses.
Number of subjects: 0
Study 30526232 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-session gait retraining program with real-time biofeedback of braking forces
Number of subjects: 12
Study 30526313 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood donation within the past 12 months
Number of subjects: 2261
Study 30526313 — intervention group
Group type: COMPARATOR
Intervention: No condomless anal intercourse (CAI)
Number of subjects: 2261
Study 30526313 — intervention group
Group type: COMPARATOR
Intervention: Belief of no undiagnosed HIV infection
Number of subjects: 2261
Study 30526313 — intervention group
Group type: COMPARATOR
Intervention: Past-12-month HIV testing
Number of subjects: 2261
Study 30526535 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial high-dose ganciclovir (6 mg)
Number of subjects: 24
Study 30526535 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance dose of ganciclovir (not specified)
Number of subjects: 24
Study 30526599 — intervention group
Group type: EXPERIMENTAL
Intervention: NK cells in BAL fluid
Number of subjects: 52
Study 30526599 — intervention group
Group type: EXPERIMENTAL
Intervention: iNKT and NKT-like cells in BAL fluid
Number of subjects: 52
Study 30526599 — intervention group
Group type: EXPERIMENTAL
Intervention: NK cells in BAL fluid of subjects that quit smoking
Number of subjects: 52
Study 30526599 — intervention group
Group type: EXPERIMENTAL
Intervention: Rate of lung function decline
Number of subjects: 52
Study 30526611 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart failure patients (n=27)
Number of subjects: 41
Study 30526611 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects (control group, n=14)
Number of subjects: 41
Study 30526617 — intervention group
Group type: EXPERIMENTAL
Intervention: Stochastic Resonance (SR) Stimulation
Number of subjects: 20
Study 30526617 — intervention group
Group type: COMPARATOR
Intervention: No stimulation
Number of subjects: 20
Study 30527084 — intervention group
Group type: EXPERIMENTAL
Intervention: RayPilot
Number of subjects: 48
Study 30527084 — intervention group
Group type: EXPERIMENTAL
Intervention: Calypso
Number of subjects: 48
Study 30527084 — intervention group
Group type: COMPARATOR
Intervention: Fiducial markers (FM) and transponders
Number of subjects: 48
Study 30527084 — intervention group
Group type: EXPERIMENTAL
Intervention: RayPilot transmitters
Number of subjects: 48
Study 30527151 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac complications (including atrial fibrillation, atrial flutter, supraventricular tachycardia, ventricular tachycardia, complete heart block, heart failure, stroke, endocarditis, myocardial infarction, pulmonary hypertension)
Number of subjects: 2731
Study 30527151 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative stroke
Number of subjects: 2731
Study 30527151 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete heart block
Number of subjects: 2731
Study 30527151 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial fibrillation
Number of subjects: 2731
Study 30527151 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial flutter
Number of subjects: 2731
Study 30527151 — intervention group
Group type: EXPERIMENTAL
Intervention: All complications between ages 5 and 17 years
Number of subjects: 2731
Study 30527203 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocan levels in patients with VAP
Number of subjects: 60
Study 30527203 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocan levels
Number of subjects: 60
Study 30527203 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum Endocan level on day 3
Number of subjects: 60
Study 30527203 — intervention group
Group type: COMPARATOR
Intervention: PCT, WBC, CRP measurements
Number of subjects: 60
Study 30527329 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir 400 mg tablets
Number of subjects: 153
Study 30527329 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir chewable tablets
Number of subjects: 153
Study 30527329 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir oral granules
Number of subjects: 153
Study 30527329 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir (all formulations)
Number of subjects: 153
Study 30527497 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin sealant (Vivostat) applied intraoperatively to the anastomosis
Number of subjects: 15
Study 30527774 — intervention group
Group type: EXPERIMENTAL
Intervention: Fondaparinux
Number of subjects: 0
Study 30527774 — intervention group
Group type: COMPARATOR
Intervention: Low-Molecular-Weight Heparin
Number of subjects: 0
Study 30527797 — intervention group
Group type: EXPERIMENTAL
Intervention: Local Anesthesia (LA)
Number of subjects: 11006
Study 30527797 — intervention group
Group type: COMPARATOR
Intervention: General Anesthesia (GA)
Number of subjects: 11006
Study 30528561 — intervention group
Group type: EXPERIMENTAL
Intervention: tazobactam/ceftolozane 1.5 g (tazobactam 0.5 g/ceftolozane 1 g) plus metronidazole 500 mg intravenously every 8 h for 60 min for 4-14 days
Number of subjects: 100
Study 30528561 — intervention group
Group type: EXPERIMENTAL
Intervention: tazobactam/ceftolozane plus metronidazole
Number of subjects: 100
Study 30528620 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary interventions (PCI) for coronary bifurcations
Number of subjects: 5036
Study 30528620 — intervention group
Group type: EXPERIMENTAL
Intervention: Independent predictors of MACE
Number of subjects: 5036
Study 30528623 — intervention group
Group type: EXPERIMENTAL
Intervention: us-TnI < 1 ng/L directly on admission
Number of subjects: 1534
Study 30528623 — intervention group
Group type: EXPERIMENTAL
Intervention: us-TnI < 2 ng/L and 0/1h delta < 1 ng/L
Number of subjects: 1534
Study 30528623 — intervention group
Group type: EXPERIMENTAL
Intervention: us-TnI ≥ 25 ng/L on admission or 0/1h delta ≥ 6 ng/L
Number of subjects: 1534
Study 30528623 — intervention group
Group type: EXPERIMENTAL
Intervention: One-year rate of death or MI
Number of subjects: 1534
Study 30529029 — intervention group
Group type: EXPERIMENTAL
Intervention: Lopinavir-ritonavir super-boosting with additional ritonavir (one-to-one ratio) during rifampicin treatment
Number of subjects: 96
Study 30529029 — intervention group
Group type: COMPARATOR
Intervention: Lopinavir-ritonavir without rifampicin
Number of subjects: 96
Study 30529085 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel IUD (52-mg, 20 mcg/d initial release)
Number of subjects: 20
Study 30529112 — intervention group
Group type: EXPERIMENTAL
Intervention: Near-syncope
Number of subjects: 3581
Study 30529112 — intervention group
Group type: COMPARATOR
Intervention: Syncope
Number of subjects: 3581
Study 30529597 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus erlotinib
Number of subjects: 19
Study 30529597 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus gefitinib
Number of subjects: 19
Study 30529905 — intervention group
Group type: EXPERIMENTAL
Intervention: Glecaprevir/pibrentasvir (G/P) for 8 or 12 weeks
Number of subjects: 1819
Study 30529905 — intervention group
Group type: EXPERIMENTAL
Intervention: Glecaprevir/pibrentasvir (G/P)
Number of subjects: 1819
Study 30530460 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based PAJ intervention
Number of subjects: 70
Study 30530460 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 70
Study 30530461 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-aided telephone support intervention
Number of subjects: 377
Study 30530461 — intervention group
Group type: COMPARATOR
Intervention: Usual care enhanced by periodic assessments
Number of subjects: 377
Study 30530463 — intervention group
Group type: EXPERIMENTAL
Intervention: Endotracheal intubation
Number of subjects: 0
Study 30530463 — intervention group
Group type: EXPERIMENTAL
Intervention: Data collection form focusing on airway management and hemodynamic management
Number of subjects: 0
Study 30530463 — intervention group
Group type: EXPERIMENTAL
Intervention: Scoring system for peri-intubation complications
Number of subjects: 0
Study 30530477 — intervention group
Group type: EXPERIMENTAL
Intervention: Arabin cervical pessary
Number of subjects: 500
Study 30530477 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (no pessary)
Number of subjects: 500
Study 30530721 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily oral therapy with tenofovir disoproxil fumarate/emtricitabine
Number of subjects: 52
Study 30530925 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg efavirenz once daily during the third trimester (3T)
Number of subjects: 42
Study 30530925 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg efavirenz once daily during the second trimester (2T)
Number of subjects: 42
Study 30530925 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg efavirenz once daily postpartum (PP)
Number of subjects: 42
Study 30530985 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral d3-l-carnitine
Number of subjects: 72
Study 30530985 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic l-carnitine supplementation
Number of subjects: 72
Study 30530985 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal metabolic transformation studies
Number of subjects: 72
Study 30531015 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal injection of Wharton's jelly-derived mesenchymal stem cells (average dose of 0.42 × 10^6 cells)
Number of subjects: 43
Study 30531219 — intervention group
Group type: EXPERIMENTAL
Intervention: Child Induction Behavioral Assessment
Number of subjects: 384
Study 30531385 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly challenging gait and balance training for 10 weeks
Number of subjects: 47
Study 30531561 — intervention group
Group type: EXPERIMENTAL
Intervention: Miscarriage
Number of subjects: 145
Study 30531561 — intervention group
Group type: EXPERIMENTAL
Intervention: Early pregnancy loss
Number of subjects: 145
Study 30531561 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous abortion
Number of subjects: 145
Study 30531561 — intervention group
Group type: EXPERIMENTAL
Intervention: Early pregnancy failure
Number of subjects: 145
Study 30531565 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel 52-mg intrauterine system (IUS)
Number of subjects: 1751